骨髓增生异常综合征转化为急性白血病的高危因素分析

刘秋艳; 王燕; 龙珍珠玛; 农卫霞; 潘歆; 章大谦; 张红霞; 吴广胜

doi:10.13201/j.issn.1004-2806.2017.07.009

骨髓增生异常综合征转化为急性白血病的高危因素分析

- 1. 新疆石河子大学医学院研究生(新疆石河子, 832000);
- 2. 新疆石河子大学医学院第一附属医院
基金项目:
石河子大学第一附属医院院级课题(No:PJ2016004)

详细信息

通讯作者: 吴广胜,E-mail:hematology@126.com

中图分类号: R733.7

收稿日期: 2017-06-02

Study on high-risk factors affecting the evolution from myelodysplastic syndrome to acute leukemia

- 1. Department of Clinical Medicine, Medical College of Shihezi University, Shihezi, 832000, China;
- 2. Department of Hematology, the First Hospital Affiliated Shihezi University

More Information

Corresponding author: WU Guangsheng, E-mail: hematology@126.com

Received Date: 02 June 2017

摘要

摘要: 目的:探讨影响骨髓增生异常综合征(MDS)转化为急性白血病的高危因素。方法:回顾性分析我院收治的101例MDS患者的转白时间、转白亚型、临床特征、实验室数据等临床资料。结果:101例MDS患者中,34.6%(35/101)转化为急性髓系白血病,中位转白时间7.5(0.5~53)个月,中位生存时间40.7(1~87)个月。单因素分析发现,染色体核型、骨髓原始细胞比例、血细胞减少系数、病态造血累及系数、WHO分型均影响MDS患者的转白率(均P<0.05)。多因素分析发现,染色体核型、病态造血系数、WHO分型是MDS向急性白血病转化的独立危险因素(均P<0.05)。转白组患者较未转白组患者的生存期明显缩短(11个月∶45个月)。结论:MDS是一类高风险向急性白血病转化的疾病,根据相关高危因素,对其进行预后评估,从而为个体化治疗提供临床依据,对延长患者转白时间及总生存时间具有重要意义。
- 骨髓增生异常综合征 /
- 白血病,急性 /
- 转白 /
- 高危因素
Abstract: Objective:To investigate factors affecting the evolution to acute leukemia of patients with myelodysplastic syndrome (MDS).Method:Time to leukemic transformation,subtypes of leukemia transformations,clinical manifestation and laboratory parameters were retrospectively analyzed in 101 MDS patients.Result:Thirty-five cases transformed to acute myeloid leukemia in 101 MDS patients,the median evolution time was 7.5(0.5 to 53) months,the median survival time was 40.7(1 to 87) months.Single factor analysis showed that karyotype,marrow blast,number and extent of cytopenias,pathological hematopoiesis and WHO subtypes all could affect the rate of MDS evolution to acute leukemia (P<0.05).Multivariate analysis by Cox model showed that WHO subtypes,karyotype and pathological hematopoiesis were independent risk factors affecting the evolution from MDS to acute leukemia (P<0.05).Conclusion:MDS is one type of disease at high risk of transforming to leukemia.According to analyzing the related factors,we can provide clinical evidence for individualized treatment stratification,and prolong the survival time and the evolution time significantly.
- myelodysplastic syndrome /
- acute leukemia /
- evolution /
- high-risk factors

HTML全文

参考文献(10)

[1]	Greenberg PL.The multifaceted nature of myelodysplastic syndromes:clinical,molecular,and biological prognostic features[J].J Natl Compr Canc Netw,2013,11:877-885.
[2]	Pellagatti A,Boultwood J.The molecular pathogenesis of the myelodysplastic syndromes[J].Eur J Haematol,2015,95:3-15.
[3]	张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2007:157-163.
[4]	Adès L,Itzykson R,Fenaux P.Myelodysplastic syndromes[J].Lancet,2014,383:2239-2252.
[5]	Neukirchen J,Lauseker M,Blum S,et al.Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome:a multicenter study[J].Leuk Res,2014,38:57-64.
[6]	Voso MT,Fenu S,Latagliata R,et al.Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System:validation by the Gruppo Romano Mielodisplasie Italian Regional D[J].J Clin Oncol,2013,31:2671-2677.
[7]	Invernizzi R,Quaglia F,Porta MG.Importance of classical morphology in the diagnosis of myelodysplastic syndrome[J].Mediterr J Hematol Infect Dis,2015,7:e2015035.
[8]	Angelova S,Spassov B,Nikolova V,et al.Does the pattern of clonal evolution in the karyotype of patients with acute myeloid leukemia and myelodysplastic syndromes depend on the type of the primary chromosomal aberrations?[J].Cytol Genet,2015,49:226-231.
[9]	Yue QF,Chen L,She XM,et al.Clinical prognostic factors in 86 Chinese patients with primary myelodysplastic syndromes and trisomy 8:a single institution experience[J].Yonsei Med J,2016,57:358-364.
[10]	徐媛媛,于力.骨髓增生异常综合征分子生物学预后标志研究进展[J].中国实验血液学杂志,2016,24(1):285-289.